Finding biomarkers in Langerhans cell histiocytosis
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This study is looking for adults with Langerhans cell histiocytosis (LCH) and also for adults with certain lung conditions (like cystic lung disease or emphysema) or healthy smokers to act as controls. The goal is to find biomarkers (signs in the body) that can help doctors diagnose LCH, predict how it will progress, and see how well treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of Langerhans cell histiocytosis (LCH) or, if you are a control, you have a lung condition like cystic lung disease or emphysema, or you are a healthy smoker.
- You agree to sign an informed consent form.
- You have health insurance.
- You are not pregnant, breastfeeding, or in a situation where you cannot freely give consent (e.g., under guardianship, in psychiatric care, or in prison).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with a specific lung condition to better understand how it behaves over time. If you have the right diagnosis, joining could help researchers learn what to expect and how to manage it.
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
This trial aims to find biological markers in people with systemic histiocytosis by analyzing blood or tissue samples. It may help better understand and manage the disease.
This trial tests a new targeted drug called luvometinib, either alone or with a standard chemotherapy drug (cytarabine), for people with Langerhans cell histiocytosis. The goal is to see if adjusting the treatment based on your response can help control the disease.
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
Hear when a new Histiocytosis, Langerhans-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.